Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in two segments: Specialty Brands, Specialty Generics and Nuclear Imaging. Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business owing to persistent macroeconomic challenges and Intrathecal Therapy business to focus on its key areas.
We expect investor focus on the performance of Acthar, Inomax and Ofirmev.
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 5.27%.
Currently, Mallinckrodt has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.73, and the company reported EPS of $1.85.
Revenue: Revenues however missed expectations. Mallinckrodt posted revenues of $824.5 million, compared to our consensus estimate of $827.3 million.
Key Stats: The top-line was under pressure due to weakness in the Specialty generics segment. Sales of Therakos were down as well.
Check back later for our full write up on this Mallinckrodt earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Image: Bigstock
Mallinckrodt (MNK) Tops Q2 Earnings, Misses on Sales
Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in two segments: Specialty Brands, Specialty Generics and Nuclear Imaging. Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business owing to persistent macroeconomic challenges and Intrathecal Therapy business to focus on its key areas.
We expect investor focus on the performance of Acthar, Inomax and Ofirmev.
Mallinckrodt PLC Price and EPS Surprise
Mallinckrodt PLC Price and EPS Surprise | Mallinckrodt PLC Quote
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 5.27%.
Currently, Mallinckrodt has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.73, and the company reported EPS of $1.85.
Revenue: Revenues however missed expectations. Mallinckrodt posted revenues of $824.5 million, compared to our consensus estimate of $827.3 million.
Key Stats: The top-line was under pressure due to weakness in the Specialty generics segment. Sales of Therakos were down as well.
Check back later for our full write up on this Mallinckrodt earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>